Author:
Goense Lucas,van Hillegersberg Richard
Publisher
Springer Science and Business Media LLC
Reference7 articles.
1. van der Zijden CJ, van der Sluis PC, Mostert B, Nuyttens JJME, Spaander VMCW, Valkema R, et al. Adjuvant therapy for patients with a tumor-positive resection margin after neoadjuvant chemoradiotherapy and esophagectomy. Ann Surg Oncol. 2024. https://doi.org/10.1245/s10434-024-14912-x
2. Raman V, Jawitz OK, Voigt SL, Yang CJ, D’Amico TA, Harpole DH Jr, et al. The role of adjuvant therapy in patients with margin-positive (R1) esophagectomy: a national analysis. J Surg Res. 2020;249:82–90. https://doi.org/10.1016/j.jss.2019.11.035.
3. Bott RK, Beckmann K, Zylstra J, Wilkinson MJ, Knight WRC, Baker CR, et al. Adjuvant therapy following oesophagectomy for adenocarcinoma in patients with a positive resection margin. Br J Surg. 2020;107:1801–10.
4. Raja S, Rice TW, Lu M, Semple ME, Blackstone EH, Murthy SC, et al. Adjuvant therapy after neoadjuvant therapy for esophageal cancer: who needs it? Ann Surg. 2023;278:e240–9.
5. Okada M, Kato K, Cho BC, Takahashi M, Lin CY, Chin K, et al. Three-year follow-up and response-survival relationship of nivolumab in previously treated patients with advanced esophageal squamous cell carcinoma (ATTRACTION-3). Clin Cancer Res. 2022;28:3277–86.